Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan Rogel Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Voluntarily provide written IRB-approved consent
Age ≥ 18 years
Histologically proven CTCL
Stage IIB-IV CTCL with ≥2 cutaneous tumors assessable for response
At least one cutaneous tumor amenable to radiation therapy. Must have at least 1 tumor assessable for response that will not undergo radiation.
Adequate organ function
Prior treatment is allowed if at least 4 weeks have elapsed since last chemotherapy and/or radiation and the subject has recovered from all treatment related toxicity
You may not be if
Prior allogeneic stem cell transplant.
Prior treatment with a PD-1/PD-L1 inhibitor
Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment.
Current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab.
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection.
History of hypersensitivity to durvalumab or any excipient
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab.
Female subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control
Male subjects who are not employing an effective method of birth control
Uncontrolled current medical illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris,unstable cardiac arrhythmia and/or psychiatric illness or other condition that in the opinion of the investigator would limit compliance with study requirements.
